Evidence reviewed: 22 July 2026 · Author: ExtolX Editorial Team · Scientific review: Pending
Educational information for laboratory research audiences. This article does not provide medical advice, dosage or administration guidance.
Selank is a synthetic heptapeptide derived from the naturally occurring immunomodulatory peptide tuftsin. Published research examines stress, behaviour and gene expression, but high-quality human evidence is limited.
Key points
- The compound is the synthetic sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, derived from tuftsin.
- Evidence from cells, animals and humans must be interpreted separately.
- Not authorised by the MHRA as a medicine; regulatory status differs internationally.
- Research findings do not establish that independently supplied material is equivalent to a clinical-trial product.
What is it?
Selank is a synthetic heptapeptide derived from the naturally occurring immunomodulatory peptide tuftsin. Published research examines stress, behaviour and gene expression, but high-quality human evidence is limited. In scientific work, identity should be established through appropriate analytical documentation rather than inferred from a product name alone.
How is it thought to work?
Preclinical work has explored GABAergic, serotonergic, immune and gene-expression effects. Multiple proposed pathways remain hypotheses rather than validated clinical mechanisms.
What does the current evidence show?
- Animal behavioural studies report changes in anxiety-related paradigms and learning tasks.
- Small regional clinical reports have examined anxiety disorders, often with limited accessible methodological detail.
- Independent large, placebo-controlled human trials supporting common enhancement claims were not identified.
Evidence snapshot
| Evidence level | What it can establish | Main caution |
|---|---|---|
| Laboratory | Biochemical activity and cellular responses under defined conditions | Does not establish effects in an intact organism |
| Animal | Mechanisms and model-specific biological responses | Translation to humans is uncertain |
| Human | Outcomes in the studied population and formulation | Must not be generalised beyond the actual trial |
What remains unknown?
- Preclinical behavioural outcomes are not equivalent to diagnosed human conditions.
- The small and geographically concentrated evidence base limits generalisability.
- Long-term safety, pharmacokinetics and interactions remain insufficiently characterised.
Regulatory and safety context
Not authorised by the MHRA as a medicine; regulatory status differs internationally. A research-use label does not override the way a product is presented, promoted or used. Safety information from one formulation or jurisdiction cannot be transferred automatically to another.
Frequently asked questions
Does published research prove a benefit?
No. A finding must be interpreted in the context of its model, study design, population, formulation and endpoints. Preliminary or preclinical findings are not proof of clinical benefit.
Is research material equivalent to material used in a clinical trial?
Not on the basis of a shared name. Equivalence would require evidence concerning identity, manufacture, purity, formulation, stability and biological activity.
References and further reading
Research-use notice: ExtolX products are supplied strictly for legitimate laboratory research. They are not intended for human or veterinary use, consumption, diagnosis, treatment or prevention of disease.